On April 3rd, HIPRA presented RESPIVAC® aMPV at the European launch event held in Ferrari Museum in Maranello (Italy), gathering over 50 poultry professionals from 13 countries across Europe. 

The event was centered on three presentations about avian metapneumovirus (aMPV), with renowned speakers who shared their expertise on the emergence of avian metapneumovirus subtypes A and B in the U.S., the prevalence of aMPV in Europe, and new strategies to prevent the disease. 

Dr. Holly Sellers, Director of the Poultry Diagnostic and Research Center (PDRC) at the University of Georgia, explained the current situation with the emergence of aMPV outbreaks in the U.S. 

Dr. Mattia Cecchinato, full professor at the Department of Animal Medicine at the University of Padova, followed with his insights based on the latest data on avian metapneumovirus prevalence in Europe which indicates that the current prevalence of aMPV in broilers is around 50-60%. 

Enrique Canceller, Global Product Manager at HIPRA, concluded the presentations with a focus on disease prevention strategies, introducing RESPIVAC® aMPV, HIPRA’s lyophilized vaccine for ocular or nasal administration via drinking water against avian metapneumovirus.

Among its numerous advantages, RESPIVAC® aMPV offers three key differentiating factors: protection against subtype B, the most prevalent and impactful worldwide, with cross-protection against subtype A. The vaccine is registered not just for broilers, but also for layers and breeders during the laying period, offering flexibility and extended protection in vaccination plans. Administered via spray or drinking water, RESPIVAC® aMPV can be used from the first to the last day of life, adapting to any vaccination schedule.

With the European launch of RESPIVAC® aMPV, HIPRA solidifies its position as a trusted leader in avian metapneumovirus control and reaffirms its commitment to improving poultry health.